Galectin Therapeutics Announces Update on Warrant Exercises

Published: Aug 28, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NORCROSS, Ga., Aug. 28, 2013 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced all of the 710,834 common stock purchase warrants scheduled to expire on August 25, 2013 have been exercised for total cash proceeds of $3 million. These proceeds add to the recently announced $3 million private placement of 500,000 shares of unregistered common stock.

Help employers find you! Check out all the jobs and post your resume.

Back to news